Giulio F. Tarro
President Foundation T.& L.de Beaumontm, Italy
US Army Medical Research Institute of Infectious Diseases
Cellular Technology Limited USA
De-chu Christopher Tang
Founder of VaxDome LLC and Vaxin Inc USA
Glenn S Tillotson
Cempra Pharmaceuticals, USA
Thermo Fisher Scientific, Inc. USA
Ph.D. President Personalized Medicine Coalition
Carlos Alberto Guzman
Helmholtz Centre for Infection Research Germany
Recommended Global Vaccines Webinars & Conferences
Europe & UK
Asia Pacific & Middle East
- Vaccine and Clinical Trials
- Vaccines Congress-2023
- Sessions and Tracks
- Market Analysis
- VISA-Trip Advisor
Vaccine and Clinical Trials
November 04- November 05, 2023 | Toronto, Canada
Conference Series LLC Ltd welcomes you to attend the 35th Annual Congress on Vaccine and Clinical Trials to be held in Toronto, Canada on November 04-05, 2023. The theme for the conference is Charting Frontiers in Vaccinology: Innovations, Insights, and Impact in Clinical Trials.
- Principal Investigators
- Medical Directors
- Directors/Executive Directors
- Vice Presidents/Senior Vice Presidents/Executive Vice Presidents
- Deans/Senior Professors/Associate Professor/Assistant Professors
- Research Scholars
- Business Entrepreneurs
- Medical Devices Manufacturing Companies
- Vaccine Manufacturing Companies
- Vaccine Developers and Investigators
- Worldwide appreciation of the profile of Researchers.
- Obtain credits for professional growth.
- Explore the latest of cutting edge analysis.
- Make long-term bonds at social and networking activities.
- An ability to advertise one page in the distribution of abstract books and flyers that ultimately gets 1 million views and adds great value to your research profile.
- Learn a transition beyond your area of interest to learn more about new subjects and studies away from your core subject of Vaccines and Clinical Trials.
- We have distinctive networking, learning and enjoyable integration into a single package.
- Each speaker has the separate Speaker profile.
- Professional Development-Improve understanding and knowledge.
- Attendance at conference supports, rejuvenates and energises delegates.
- Your involvement in our conference will help with a new methodology and ideology that can be used to broaden the outcomes of businesses or industries.
- Opportunities for Vaccines researchers and experts in the same field to meet and exchange new ideas through an conference.
- Exposure to the international environment would increase the possibility of new companies.
- Opportunity to demonstrate your company's latest technologies, new products, or service your business to a wide range of international participants.
- Increase business by our conference participants through lead generation.
- It takes a lot of time, effort and drive to create a successful company, so it's always nice to have a network of colleagues and associates to draw energy from individuals who share a common drive and objective.
- Conferences in vaccines provide opportunities for more attention and contemplation that could help you move your company to the next stage.
- Benchmarking main organization plans and moving it forward.
- Get feedback from trustworthy people at our conference to your company questions and challenges.
- On our conference banner, website and other proceedings, branding and marketing content, the advertising logo of your company.
- Nobody has this massive visitors to Vaccines and Clinical Trials in the world, this is the best forum to highlight society.
- Creating long-lasting peer relationships.
- In our conference banner, website and other proceedings, branding and marketing material, promotional content and your Organization logo will increase your number of subscribers/members by 40%.
- The exposure of our event to your Company listing in the Global Business forum will have a great effect on your association.
- Your representatives can network to update their knowledge and understanding of your organisation and services with key conference delegates.
- Vaccines advertising materials such as posters, brochures, pamphlets, services that will be circulated to hospitals, universities, society and researchers will be integrated with information.
Sessions and Tracks
Cancer vaccines are a form of immunotherapy that can help educate the immune system about what cancer cells “look like” so that it can recognize and eliminate them.
Vaccines have proven effective in preventing diseases caused by viruses and bacteria. Since the first vaccine was developed more than 200 years ago, they have prevented some of the twentieth century’s deadliest diseases and have helped save hundreds of millions of lives globally.
In the case of diseases caused by viruses (e.g., measles, polio, and smallpox) and bacteria (e.g., diphtheria, tetanus, and tuberculosis), vaccines work by exposing people to a weakened or inactivated version of the threat. This enables their immune system to identify these threats according to their specific markers—known as “antigens”—and mount a response against them. These vaccines typically work best in the preventive setting, when an individual is given the vaccine before being infected by the bacteria or virus.
In the case of cancer, however, the situation is more complicated for several reasons (more below) and this has made it more difficult to develop vaccines to either prevent or treat cancer. In particular, unlike bacteria and viruses, which appear foreign to our immune system, cancer cells more closely resemble our normal, healthy cells. Furthermore, each individual’s tumor is in some sense unique and has its own distinguishing antigens. As a result, more sophisticated approaches are necessary to develop effective cancer vaccines.
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Personalized Neoantigen Vaccines
Preventive Cancer Vaccines:
Viral infections are responsible for the development of several cancers and preventive vaccines play an important role in reducing risk. For instance, cervical cancer and head and neck cancer can be caused by human papilloma virus, or HPV, whereas liver cancer can be caused by hepatitis B virus or HBV. Several vaccines have been developed that can prevent HBV and HPV infection and, as a result, protect against the formation of HBV- and HPV-related cancers.
Four of these preventive cancer vaccines have been approved by the U.S. Food and Drug Administration (FDA).
Therapeutic Cancer Vaccines:
Each individual’s tumor is in some sense unique and has its own distinguishing antigens. As a result, more sophisticated cancer vaccine approaches are necessary. Fortunately, doctors can now identify targets on patients’ tumors that can help distinguish cancer cells from their normal cells. Sometimes these targets are normal proteins that are produced at abnormally high levels by cancer cells, such as prostatic acid phosphatase (PAP), which is often overexpressed by prostate cancer cells. Taking advantage of that insight, the sipuleucel-T vaccine was developed and received FDA approval in 2010 for the treatment of patients with advanced prostate cancer. Additionally, virus-derived proteins expressed by virus-infected cancer cells offer another promising source of markers that can be targeted through vaccines. Another exception is Bacillus Calmette-Guérin, or BCG, a tuberculosis vaccine that acts as a general immune stimulant. In 1990, BCG became the first immunotherapy of any type to be approved by the FDA and is still used for the treatment of early-stage bladder cancer.
The global vaccines market has witnessed remarkable growth over the past few decades, driven by advancements in medical research, increasing awareness about preventive healthcare, and the ongoing pursuit of controlling and eradicating infectious diseases. Clinical trials play a pivotal role in the development, evaluation, and approval of vaccines, ensuring their safety, efficacy, and suitability for widespread use. This market analysis delves into the key trends, drivers, challenges, and opportunities in the vaccines and clinical trials landscape.
Rising Demand for Preventive Healthcare: The increasing emphasis on preventive healthcare has elevated the demand for vaccines. Governments, organizations, and individuals recognize the significance of vaccination in curbing the spread of infectious diseases and reducing the burden on healthcare systems.
Technological Advancements: Innovations in biotechnology, genomics, and immunology have accelerated vaccine development. This has led to the creation of novel vaccine platforms, such as mRNA vaccines, that have shown immense potential in addressing diseases like COVID-19.
Global Health Initiatives: International efforts to eliminate diseases like polio, measles, and malaria have spurred investment in vaccine research and clinical trials. Public-private partnerships and collaborations are driving research forward, aiming to tackle diseases that disproportionately affect developing nations.
Personalized Vaccines: The concept of personalized medicine is making its way into the vaccine landscape. Tailoring vaccines to individual genetic profiles could enhance efficacy and reduce adverse effects, making clinical trials even more crucial in understanding these personalized responses.
Pandemic Preparedness: The COVID-19 pandemic underscored the urgency of vaccine development and the vital role of clinical trials. Governments and organizations worldwide are now investing more in vaccine research to be better prepared for future health crises.
Growing Disease Burden: The prevalence of infectious diseases like HIV, tuberculosis, and emerging pathogens necessitates continuous vaccine research. Clinical trials are essential to evaluate new vaccines and their potential impact on disease transmission.
Changing Epidemiology: Shifting demographics, urbanization, and global travel patterns impact disease transmission dynamics. As diseases cross borders more easily, effective vaccines become imperative, making clinical trials essential to address changing epidemiological trends.
Regulatory Hurdles: The regulatory process for vaccine approval can be lengthy and complex due to safety concerns. Balancing the need for rigorous testing with the urgency of addressing public health threats presents challenges.
Resource Constraints: Conducting clinical trials requires significant financial resources and skilled personnel. In resource-limited settings, this can hinder the timely development and evaluation of vaccines.
Vaccine Hesitancy: Misinformation and vaccine hesitancy pose obstacles to vaccine adoption. Ensuring public trust in vaccines necessitates transparent communication and evidence from robust clinical trials.
Innovative Trial Designs: Adaptive trial designs and real-world evidence integration can accelerate the vaccine development process while maintaining safety and efficacy evaluations.
Collaborative Research: Partnerships between academia, industry, and governments can leverage diverse expertise and resources, expediting vaccine research and development.
Emerging Markets: Developing countries present untapped opportunities for vaccine market growth. Tailored vaccine solutions and affordable clinical trial strategies can address specific regional health challenges.
The vaccines and clinical trials market is witnessing a dynamic evolution driven by scientific innovation, global health priorities, and a renewed understanding of the critical role vaccines play in disease prevention. While challenges exist, the opportunities for accelerated vaccine development, personalized medicine, and global health impact through collaborative efforts are substantial. As technology continues to shape the landscape, the role of clinical trials in ensuring safe, effective, and globally accessible vaccines remains paramount.
- The global vaccine market was valued at $58.4 billion in 2020 and is projected to reach $108.5 billion by 2027, with a CAGR of 9.3% from 2021 to 20271.
- In 2020, clinical trials for COVID-19 vaccines saw unprecedented speed, with multiple vaccines reaching phase III trials within months2.
- Vaccine hesitancy resulted in a decline in measles vaccination rates, contributing to a 30% increase in reported measles cases globally between 2016 and 20193.
- Developing countries accounted for 64% of vaccine doses administered globally in 2019, reflecting the importance of global health initiatives4.
Grand View Research, "Vaccine Market Size, Share & Trends Analysis Report," 2021. â†©
World Health Organization, "DRAFT landscape and tracker of COVID-19 candidate vaccines," 2020. â†©
World Health Organization, "Measles cases spike globally due to gaps in vaccination coverage," 2019. â†©
UNICEF, "Immunization coverage," 2020. â†©